Vanda Pharmaceuticals Inc. VNDA

What this company does

Vanda Pharmaceuticals Inc.'s commercial portfolio is comprised of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder and for nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis, and NEREUS for the prevention of vomiting induced by motion. The company's revenues are generated from product sales concentrated in a limited number of specialty pharmacies, specialty distributors and wholesalers, and four major customers each accounted for more than 10% of total revenues for 2025, together representing 76% of total revenues for the year ended December 31, 2025. The company had 533 full-time employees as of December 31, 2025, compared with 368 employees as of December 31, 2024. Vanda Pharmaceuticals Inc. was incorporated in Delaware in 2002 and maintains its principal executive offices in Washington, D.C.

Written from the business description in Vanda Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.